Literature DB >> 21437098

Optimizing weight control in diabetes: antidiabetic drug selection.

S Kalra1, B Kalra, Ag Unnikrishnan, N Agrawal, S Kumar.   

Abstract

CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?
RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.

Entities:  

Keywords:  diabetes; weight control

Year:  2010        PMID: 21437098      PMCID: PMC3047980          DOI: 10.2147/DMSOTT.S11941

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


Weight control in diabetes

Definition: Weight control is an important aspect of diabetes treatment, and can improve glycemic control and cardiovascular risk factors per se.1,2 The term “diabesity” is used to define the pathogenic relationship between diabetes and obesity.3 Incidence: Glycemic control using conventional drugs is usually associated with weight gain.3 A head-to-head comparison of various treatment modalities regarding the incidence of weight gain has not been done. Economics: No published study has addressed the direct cost of weight gain during diabetes treatment. However, weight loss has been shown to reduce medical and pharmaceutical costs in patients with diabetes.4 Drugs which are relatively more cost-effective, such as sulfonylureas, may not end up being cheaper if they increase the overall costs of therapy, and studies are needed to address this issue. Level of evidence: Systemic reviews, meta-analysis, randomized controlled trials, guidelines. Search sources: PubMed, Cochrane Library, Google Scholar. Outcomes: Both physicians and patients seek: Minimum weight gain in patients of normal weight Weight loss in overweight patients Consumer summary: Patients with diabetes tend to gain weight when given antidiabetic drugs. There is good evidence that metformin, insulin detemir, and newer drugs such as liraglutide prevent weight gain when prescribed alone, or in combination with other drugs.

The evidence

Do antidiabetic drugs increase or decrease weight?

Systematic reviews5,6 and meta-analysis have concluded that pioglitazone and rosiglitazone lead to weight gain. The combined use of metformin and the thiazolidinediones shows controversial results related to weight gain. Sulfonylurea use is linked to significant weight gain.7 Addition of sulfonylureas to metformin is also associated with weight gain, but to a lesser degree, according to meta-analysis. 8 A meta-analysis has shown that a combination of sulfonylureas and insulin does not lead to weight gain.9 Metformin has been shown to reduce weight, as compared with sulfonylureas, in meta-analysis.10 Metformin, when used as cotherapy, also mitigates the weight gain seen with sulfonylureas and repaglinide.11 Alpha-glucosidase inhibitors have an insignificant effect on weight, as per a meta-analysis of 41 studies.12 A randomized controlled trial shows that voglibose coadministration can reduce the weight gain associated with pioglitazone use.13 Other meta-analysis shows that the DPP-4 inhibitors, such as vildagliptin and sitagliptin, are weight-neutral,14 while the GLP-1 analogs, ie, liraglutide and exenatide, are associated with weight loss. Insulin detemir is the only insulin to show weight loss or reduced weight gain consistently in overweight patients in meta-analysis.15 Results with other insulin preparations are conflicting.16 Insulin glargine use causes more weight gain than Neutral Protamine Hagedorn insulin.17 Weight control and glycemic control should be aimed for Weight gain may mitigate the benefits achieved by glycemic control Try to combine regimes with metformin, but keep a watch for contraindications and side effects of metformin Avoid using a combination of medications which cause weight gain Avoid overdosage of insulin, which may lead to weight gain by causing hypoglycemia and increased snacking. Reinforce diet and physical activity as effective methods of glycemic and weight control1 Optimal choice of antidiabetic drugs can help avoid excessive weight gain5 Specialist referral will rarely be needed to optimize weight control. Measure weight, waist and hip circumference, and watch for edema regularly in all patients with diabetes Presence of edema or waist gain should prompt a review of antidiabetic, as well as other, medications. If possible, discontinue or replace thiazolidinediones if excessive weight gain occurs with their use, or is to be avoided Reduce the dose of insulin, especially rapid-acting insulin if patients complain of excessive weight gain associated with hypoglycemia Shift to insulin detemir if indicated Add/increase the dose of metformin, to maximally tolerated levels Use GLP-1 analogs, such as liraglutide and exenatide, if weight gain is an issue.
Systematic reviews> 10
Meta-analyses> 10
Randomized controlled trials> 100 have been published.
  17 in total

1.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.

Authors:  Floris A van de Laar; Peter L Lucassen; Reinier P Akkermans; Eloy H van de Lisdonk; Guy E Rutten; Chris van Weel
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.

Authors:  S Del Prato; D W Erkelens; M Leutenegger
Journal:  Acta Diabetol       Date:  2003-03       Impact factor: 4.280

3.  Efficacy of metformin in the treatment of NIDDM. Meta-analysis.

Authors:  K Johansen
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

Review 4.  Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes.

Authors:  S L Norris; X Zhang; A Avenell; E Gregg; T J Brown; C H Schmid; J Lau
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 5.  Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies.

Authors:  James W Anderson; Cyril W C Kendall; David J A Jenkins
Journal:  J Am Coll Nutr       Date:  2003-10       Impact factor: 3.169

6.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.

Authors:  J L Johnson; S L Wolf; U M Kabadi
Journal:  Arch Intern Med       Date:  1996-02-12

Review 7.  Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.

Authors:  D S Lasserson; P Glasziou; R Perera; R R Holman; A J Farmer
Journal:  Diabetologia       Date:  2009-07-31       Impact factor: 10.122

8.  Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).

Authors:  Anne M Wolf; Mir Siadaty; Beverly Yaeger; Mark R Conaway; Jayne Q Crowther; Jerry L Nadler; Viktor E Bovbjerg
Journal:  J Am Diet Assoc       Date:  2007-08

9.  United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

Authors: 
Journal:  BMJ       Date:  1995-01-14

Review 10.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Authors:  Renee E Amori; Joseph Lau; Anastassios G Pittas
Journal:  JAMA       Date:  2007-07-11       Impact factor: 56.272

View more
  1 in total

Review 1.  The regulatory role of DPP4 in atherosclerotic disease.

Authors:  Lihua Duan; Xiaoquan Rao; Chang Xia; Sanjay Rajagopalan; Jixin Zhong
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.